نتایج جستجو برای: hpv16 l1 vlp

تعداد نتایج: 35265  

Journal: :Journal of virology 2016
T Klymenko H Hernandez-Lopez A I MacDonald J M Bodily S V Graham

UNLABELLED The human papillomavirus (HPV) life cycle is tightly linked to differentiation of the infected epithelial cell, suggesting a sophisticated interplay between host cell metabolism and virus replication. Previously, we demonstrated in differentiated keratinocytes in vitro and in vivo that HPV type 16 (HPV16) infection caused increased levels of the cellular SR splicing factors (SRSFs) S...

2015
F. C. Mariz E. C. Coimbra A. L. S. Jesus L. M. Nascimento F. A. G. Torres A. C. Freitas

The human papillomavirus (HPV) L1 major capsid protein, which forms the basis of the currently available vaccines against cervical cancer, self-assembles into virus-like particles (VLPs) when expressed heterologously. We report the development of a biotechnology platform for HPV16 L1 protein expression based on the constitutive PGK1 promoter (PPGK1) from the methylotrophic yeast Pichia pastoris...

2014
Giovanni Cardone Adam L. Moyer Naiqian Cheng Cynthia D. Thompson Israel Dvoretzky Douglas R. Lowy John T. Schiller Alasdair C. Steven Christopher B. Buck Benes L. Trus

Papillomaviruses are a family of nonenveloped DNA viruses that infect the skin or mucosa of their vertebrate hosts. The viral life cycle is closely tied to the differentiation of infected keratinocytes. Papillomavirus virions are released into the environment through a process known as desquamation, in which keratinocytes lose structural integrity prior to being shed from the surface of the ski...

2011
Heng Ding Cheguo Tsai Ramona Alikiiteaga Gutiérrez Fan Zhou Philippe Buchy Vincent Deubel Paul Zhou

BACKGROUND Although DNA plasmid and virus-like particle (VLP) vaccines have been individually tested against highly pathogenic avian influenza (HPAI) H5N1 viruses, the combination of both vaccines into a heterologous prime-boost strategy against HPAI H5N1 viruses has not been reported before. METHODOLOGY/PRINCIPAL FINDINGS We constructed DNA plasmid encoding H5HA (A/Shenzhen/406H/06, subclade...

2011
Ebenezer Tumban Julianne Peabody David S. Peabody Bryce Chackerian

BACKGROUND Current human papillomavirus (HPV) vaccines that are based on virus-like particles (VLPs) of the major capsid protein L1 largely elicit HPV type-specific antibody responses. In contrast, immunization with the HPV minor capsid protein L2 elicits antibodies that are broadly cross-neutralizing, suggesting that a vaccine targeting L2 could provide more comprehensive protection against in...

Journal: :International journal of clinical and experimental pathology 2015
Hong-Chao Dong Xiao-Bin Cui Liang-Hai Wang Man Li Yao-Yuan Shen Jian-Bo Zhu Cheng-Fang Li Jian-Ming Hu Shu-Gang Li Lei Yang Wen-Jie Zhang Yun-Zhao Chen Feng Li

BACKGROUND Many studies have suggested a relationship between human papillomavirus (HPV) infection and the risk of esophageal squamous cell carcinoma (ESCC). However, findings are inconclusive, potentially because of geographic heterogeneity and variations in detection methods. OBJECTIVES We sought to further investigate the prevalence of HPV with a new detection method, the MassARRAY Sequeno...

Journal: :PLoS Pathogens 2009
Christiane Stahl-Hennig Martin Eisenblätter Edith Jasny Tamara Rzehak Klara Tenner-Racz Christine Trumpfheller Andres M. Salazar Klaus Überla Karen Nieto Jürgen Kleinschmidt Reiner Schulte Lutz Gissmann Martin Müller Anna Sacher Paul Racz Ralph M. Steinman Mariagrazia Uguccioni Ralf Ignatius

Toll-like receptor (TLR) ligands are being considered as adjuvants for the induction of antigen-specific immune responses, as in the design of vaccines. Polyriboinosinic-polyribocytoidylic acid (poly I:C), a synthetic double-stranded RNA (dsRNA), is recognized by TLR3 and other intracellular receptors. Poly ICLC is a poly I:C analogue, which has been stabilized against the serum nucleases that ...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2015
Susan Hariri Elizabeth R Unger Sean Schafer Linda M Niccolai Ina U Park Karen C Bloch Nancy M Bennett Martin Steinau Michelle L Johnson Lauri E Markowitz

BACKGROUND Two currently available vaccines targeting human papillomavirus (HPV) types 16 and 18 could prevent 70% of cervical cancers and 50% of high-grade cervical lesions. Next-generation vaccines against additional types, such as a candidate 9-valent vaccine against HPV6/11/16/18/31/33/45/52/58, could further reduce HPV-associated disease burden. METHODS HPV was typed in archived tissues ...

2011
Zigui Chen Mark Schiffman Rolando Herrero Rob DeSalle Kathryn Anastos Michel Segondy Vikrant V. Sahasrabuddhe Patti E. Gravitt Ann W. Hsing Robert D. Burk

BACKGROUND Human papillomavirus 16 (HPV16) species group (alpha-9) of the Alphapapillomavirus genus contains HPV16, HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. These HPVs account for 75% of invasive cervical cancers worldwide. Viral variants of these HPVs differ in evolutionary history and pathogenicity. Moreover, a comprehensive nomenclature system for HPV variants is lacking, limiting compar...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2004
A Mandic T Vujkov

Cervical cancer is the major cause of death in women of reproductive age in parts of the developing world. Thanks to the effectiveness of national screening programs, the incidence and mortality rates for cervical cancer have declined dramatically in developed countries. According to many researchers, human papillomavirus (HPV) infection has an important role in the development of cervical neop...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید